Report LibraryAll Reports
Datamonitor Healthcare Oncology: Tumor Lysis Syndrome (TLS) Market Spotlight
Retail Price: $2,995.00*BioMedTracker Subscriber Price: $2,095.00 - click here to log in
June 15, 2018Tumor lysis syndrome (TLS) comprises of a group of metabolic disturbances that result from either chemotherapy or spontaneously induced tumor cell death. The release of intracellular components, including nucleic acids, electrolytes, and proteins, into the systemic circulation is triggered by tumor cytotoxicity. This may result in the development of metabolic abnormalities such as hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia. Clinically, this can lead to effects on multiple organs such as cardiac arrhythmias, seizures, and acute kidney injury.
This Datamonitor Healthcare report contains a Market Spotlight module.
|Indications Covered:||Tumor Lysis Syndrome (TLS)|